Compare Novavax Inc (NVAX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Union Pacific Corporation — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Union Pacific Corporation trades at $285.05 (market cap $171.36B). The key difference: Union Pacific Corporation is far larger — about 102× Novavax Inc's market cap, and Union Pacific Corporation pays a 1.97% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | UNP | |
|---|---|---|
Market Cap | $1.68B | $171.36B |
Sector | Health | Industrials |
52-Week High | $11.19 | $310.62 |
52-Week Low | $6.22 | $214.91 |
Enterprise Value | $1.26B | $200.42B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Union Pacific (UNP) trades at $288.45, down 0.4% on the day, with a bearish technical signal but strong fundamentals including a 28.85% net income margin and robust cash flow. Recent earnings beats in Q1 and Q2 2026, coupled with a pending Norfolk Southern merger expected to close by late 2027, highlight growth potential. The stock is supported by a consensus analyst price target of $334.33, indicating 16% upside.
The outlook is positive due to solid profitability and merger prospects, but risks include regulatory hurdles for the merger and economic sensitivity. Analysts are predominantly bullish (58.7% buy ratings), though technical indicators suggest near-term caution with support at $287.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
